Growth Hormone Disorders Completed Phase 1 Trials for Somapacitan (DB15093)

Also known as: Growth Hormone Disorder

IndicationStatusPhase
DBCOND0036845 (Growth Hormone Disorders)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03212131Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.Treatment
NCT03186495Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal FunctionTreatment
NCT01973244A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone DeficiencyTreatment
NCT01706783A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone DeficiencyTreatment
NCT01514500First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy SubjectsTreatment